Allopurinol: insights from studies of dose-response relationships. - Test2 - elhamkhani - TriplyDB

Allopurinol: insights from studies of dose-response relationships.

Allopurinol: insights from studies of dose-response relationships.

http://www.wikidata.org/entity/Q30240163

about

Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.

P2860

Q48191847-25D99133-67D1-40EE-83AE-A1FDF4DDE8E6

P2860

Allopurinol: insights from studies of dose-response relationships.

http://www.wikidata.org/entity/Q30240163

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Allopurinol: insights from studies of dose-response relationships.

@ast

Allopurinol: insights from studies of dose-response relationships.

@en

type

label

Allopurinol: insights from studies of dose-response relationships.

@ast

Allopurinol: insights from studies of dose-response relationships.

@en

prefLabel

Allopurinol: insights from studies of dose-response relationships.

@ast

Allopurinol: insights from studies of dose-response relationships.

@en

P1433

Q30240163-856945F2-A023-4C01-8E85-29F04ADCB0D5

P1476

Q30240163-84820601-D40F-4EE2-BB6E-7968DE9F87BC

P2093

Q30240163-38F906F8-7E32-4A0A-ADCA-7078D776A76C

Q30240163-74037779-4BEA-4418-AABC-8F4B8D6C749C

Q30240163-A7DCACC5-F63D-4633-B493-70FC36FFB83F

Q30240163-BFBCDFEE-B52E-4C2E-BD5E-CA406123DD6B

Q30240163-F5726E02-5F24-4942-8FDC-93961219897A

P2860

Q30240163-00F89FA1-9C53-499C-A00A-20C292FCEB03

Q30240163-02B4A769-6EFB-4642-BCE1-FDFE097B9384

Q30240163-04BE871C-65E0-469D-91BC-D7A2DBF919BD

Q30240163-0984B7B3-B150-426E-AFF5-9F20AF7BEEF3

Q30240163-09C47510-252C-41E2-9B59-8F8E6337105C

Q30240163-0A67800E-3A8D-4968-8A72-9E6A55F740D3

Q30240163-0F2171CE-DB1C-40DF-8129-58C027B4C9D6

Q30240163-14AC26A4-5F1F-4AB4-8775-12510FF2B28A

Q30240163-15C603BE-BB88-445B-B27E-EF6D78789003

Q30240163-176C254A-4B5E-42FC-9030-0AF9FF5212AB

P304

Q30240163-A0EF8424-B598-433F-AEC7-C812A91A9090

P31

Q30240163-3E07A941-3AAB-4664-B6E6-7F552106167C

P356

Q30240163-86AD1F8B-8F87-4701-81D5-2C45CFA038EC

P407

Q30240163-56F39FAB-AC57-4EB0-AA51-9A96284621E1

P433

Q30240163-A515A13F-2479-4302-AE22-B880064412CB

P478

Q30240163-2A71AF75-B7B9-42E6-80D5-2E42D0DD102E

P50

Q30240163-1FBEFDAC-A794-423C-8AB2-B21FEE72E89D

P577

Q30240163-3A43695E-16EC-468C-8D96-79D2337CE6CA

P698

Q30240163-017A941D-41A6-4DB8-BF38-8B7A64D1E8FA

P356

17425255.2017.1269745

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Allopurinol: insights from studies of dose-response relationships

@en

P2093

Diluk R W Kannangara

http://www.w3.org/2001/XMLSchema#string

Garry G Graham

http://www.w3.org/2001/XMLSchema#string

Kenneth M Williams

http://www.w3.org/2001/XMLSchema#string

Richard O Day

http://www.w3.org/2001/XMLSchema#string

Sophie L Stocker

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations

Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Genome-wide association analyses identify 18 new loci associated with serum urate concentrations

1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout

P304

449-462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1269745

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27927043

http://www.w3.org/2001/XMLSchema#string